The effects of DEX are not limited to its interactions with alpha2-adrenergic receptors. Inhibitory effects on I(K(DR)) and I(Na) constitute one of the underlying mechanisms through which DEX and its structurally related compounds might affect neuronal activity in vivo.
Abstract. Ranolazine, a piperazine derivative, is currently approved for the treatment of chronic angina. However, its ionic mechanisms in other types of cells remain unclear, although it is thought to be a selective blocker of late Na + current. This study was conducted to evaluate the possible effects of ranolazine on Na, and Ca
2+-activated K + current (I K(Ca) ) in pituitary tumor (GH 3 ) cells. Ranolazine depressed the transient and late components of I Na with different potencies. This drug exerted an inhibitory effect on I K(IR) with an IC 50 value of 0.92 μM, while it slightly inhibited I K(DR) and I K(Ca) . It shifted the steady-state activation curve of I K(IR) to more positive potentials with no change in the gating charge of the channel. Ranolazine (30 μM) also reduced the activity of large-conductance Ca
2+-activated K + channels in HEK293T cells expressing α-hSlo. Under current-clamp conditions, low concentrations (e.g., 1 μM) of ranolazine increased the firing of action potentials, while at high concentrations (≥10 μM), it diminished the firing discharge. The exposure to ranolazine also suppressed I Na and I K(IR) effectively in NG108-15 neuronal cells. Our study provides evidence that ranolazine could block multiple ion currents such as I Na and I K(IR) and suggests that these actions may contribute to some of the functional activities of neurons and endocrine or neuroendocrine cells in vivo.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.